Millennium Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-556,264
| Closed | -$56.7M | – | 6762 |
|
|
2023
Q2 | $56.7M | Buy |
556,264
+342,204
| +160% | +$32.4M | 0.03% | 651 |
|
|
2023
Q1 | $19.5M | Sell |
214,060
-549,212
| -72% | -$32.2M | 0.01% | 1350 |
|
|
2022
Q4 | $29M | Buy |
763,272
+141,179
| +23% | +$4.86M | 0.02% | 1134 |
|
|
2022
Q3 | $15.6M | Buy |
622,093
+469,627
| +308% | +$13M | 0.01% | 1607 |
|
|
2022
Q2 | $4.63M | Sell |
152,466
-86,175
| -36% | -$2.57M | ﹤0.01% | 2887 |
|
|
2022
Q1 | $7.82M | Sell |
238,641
-370,310
| -61% | -$11M | ﹤0.01% | 2436 |
|
|
2021
Q4 | $16.1M | Buy |
608,951
+604,688
| +14,185% | +$46.8M | 0.01% | 1655 |
|
|
2021
Q3 | $429K | Buy |
+4,263
| New | +$500K | ﹤0.01% | 5485 |
|
|
2021
Q2 | – | Sell |
-55,723
| Closed | -$5.56M | – | 7307 |
|
|
2021
Q1 | $5.56M | Sell |
55,723
-97,920
| -64% | -$11.4M | ﹤0.01% | 2455 |
|
|
2020
Q4 | $19M | Sell |
153,643
-128,364
| -46% | -$16.9M | 0.01% | 1106 |
|
|
2020
Q3 | $27.5K | Sell |
282,007
-36,170
| -11% | -$4.52M | 0.03% | 614 |
|
|
2020
Q2 | $49.6M | Buy |
318,177
+95,871
| +43% | +$14.6M | 0.07% | 289 |
|
|
2020
Q1 | $32.1M | Buy |
222,306
+8,623
| +4% | +$1.66M | 0.07% | 280 |
|
|
2019
Q4 | $43.7M | Buy |
213,683
+21,108
| +11% | +$3.85M | 0.05% | 433 |
|
|
2019
Q3 | $15.5M | Sell |
192,575
-230,286
| -54% | -$19.5M | 0.02% | 966 |
|
|
2019
Q2 | $39.9M | Sell |
422,861
-66,064
| -14% | -$5.7M | 0.06% | 434 |
|
|
2019
Q1 | $41.8M | Buy |
488,925
+353,267
| +260% | +$29.3M | 0.06% | 408 |
|
|
2018
Q4 | $7.61M | Buy |
135,658
+36,116
| +36% | +$2.21M | 0.01% | 1294 |
|
|
2018
Q3 | $8.14M | Buy |
99,542
+90,761
| +1,034% | +$6.4M | 0.01% | 1455 |
|
|
2018
Q2 | $307K | Buy |
+8,781
| New | +$267K | ﹤0.01% | 3381 |
|
|
2017
Q4 | – | Sell |
-37,147
| Closed | -$1.16M | – | 4169 |
|
|
2017
Q3 | $1.16M | Buy |
+37,147
| New | +$1.12M | ﹤0.01% | 2441 |
|
|
2017
Q2 | – | Sell |
-32,108
| Closed | -$727K | – | 3980 |
|
|
2017
Q1 | $727K | Sell |
32,108
-11,446
| -26% | -$283K | ﹤0.01% | 2576 |
|
|
2016
Q4 | $951K | Buy |
+43,554
| New | +$1.1M | ﹤0.01% | 2281 |
|
Other funds holding RETA
Millennium Management's RETA Position: Q3 2023 in Review
Millennium Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 556,264 shares — an estimated $56.7M sold.
Millennium Management first reported a position in RETA in Q4 2016 and held it in 23 quarters. The position peaked at $56.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Millennium Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Millennium Management sold 556,264 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $56.7M.
- Millennium Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 23 quarters.
- Millennium Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $56.7M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.